WO2010147375A3 - Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same - Google Patents

Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same Download PDF

Info

Publication number
WO2010147375A3
WO2010147375A3 PCT/KR2010/003853 KR2010003853W WO2010147375A3 WO 2010147375 A3 WO2010147375 A3 WO 2010147375A3 KR 2010003853 W KR2010003853 W KR 2010003853W WO 2010147375 A3 WO2010147375 A3 WO 2010147375A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
vegf
screening
searched
inhibitor
Prior art date
Application number
PCT/KR2010/003853
Other languages
French (fr)
Korean (ko)
Other versions
WO2010147375A2 (en
Inventor
강인철
박찬원
Original Assignee
주식회사 이노파마스크린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 이노파마스크린 filed Critical 주식회사 이노파마스크린
Priority to US13/379,213 priority Critical patent/US20120101284A1/en
Priority to EP10789702A priority patent/EP2444815A2/en
Priority to JP2012515976A priority patent/JP2012530896A/en
Publication of WO2010147375A2 publication Critical patent/WO2010147375A2/en
Publication of WO2010147375A3 publication Critical patent/WO2010147375A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a compound obtained by screening for the substance which inhibits binding between beta amyloid 1-42 peptide and VEGF 165. The inhibitory substance screened in accordance with the present invention can be valuably used as a substance for treating Alzheimer's disease.
PCT/KR2010/003853 2009-06-17 2010-06-15 Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same WO2010147375A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/379,213 US20120101284A1 (en) 2009-06-17 2010-06-15 Method for screening inhibitor for inhibiting interaction between beta-amyloid peptide and vegf and inhibitor searched by the same
EP10789702A EP2444815A2 (en) 2009-06-17 2010-06-15 Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same
JP2012515976A JP2012530896A (en) 2009-06-17 2010-06-15 Method for searching for substance that suppresses interaction between beta amyloid peptide and VEGF, and inhibitor searched by the method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0054085 2009-06-17
KR1020090054085A KR101095630B1 (en) 2009-06-17 2009-06-17 A method for screening a compound of inhibiting interaction between beta-amyloid and VEGF and beta-amyloid inhibitor thereof

Publications (2)

Publication Number Publication Date
WO2010147375A2 WO2010147375A2 (en) 2010-12-23
WO2010147375A3 true WO2010147375A3 (en) 2011-03-24

Family

ID=43356900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003853 WO2010147375A2 (en) 2009-06-17 2010-06-15 Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same

Country Status (5)

Country Link
US (1) US20120101284A1 (en)
EP (1) EP2444815A2 (en)
JP (1) JP2012530896A (en)
KR (1) KR101095630B1 (en)
WO (1) WO2010147375A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005780A1 (en) * 1995-08-08 1997-02-20 The University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease related proteins and uses thereof
WO1997044669A1 (en) * 1996-05-23 1997-11-27 Medical Research Council Screening of agents for treatment of alzheimer's disease
WO2002048898A1 (en) * 2000-12-12 2002-06-20 Prana Biotechnology Limited Method for screening for inhibitors of alzheimer's disease
US20090028869A1 (en) * 2007-01-11 2009-01-29 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237518B8 (en) 2002-06-11 2009-03-12 Arqule, Inc. Substituted phenylsulfonamide inhibitors of beta amyloid production
JP4813371B2 (en) 2004-01-16 2011-11-09 サノフイ−アベンテイス Acylaminothiazole derivatives and their use as β-amyloid inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005780A1 (en) * 1995-08-08 1997-02-20 The University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease related proteins and uses thereof
WO1997044669A1 (en) * 1996-05-23 1997-11-27 Medical Research Council Screening of agents for treatment of alzheimer's disease
WO2002048898A1 (en) * 2000-12-12 2002-06-20 Prana Biotechnology Limited Method for screening for inhibitors of alzheimer's disease
US20090028869A1 (en) * 2007-01-11 2009-01-29 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases

Also Published As

Publication number Publication date
WO2010147375A2 (en) 2010-12-23
US20120101284A1 (en) 2012-04-26
JP2012530896A (en) 2012-12-06
EP2444815A2 (en) 2012-04-25
KR20100135610A (en) 2010-12-27
KR101095630B1 (en) 2011-12-19

Similar Documents

Publication Publication Date Title
EP1921137A4 (en) Antibody having inhibitory effect on amyloid fibril formation
EP2180435A4 (en) Compound property prediction apparatus, property prediction method and program for executing the method
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
EP1922023A4 (en) Method for treating myocardial rupture
EP2155009A4 (en) Automated tightening shoe
ZA201008303B (en) Methods for treating neurodegenerative disorders related to neurofibrillary tangles.
CL2008000322A1 (en) PROCESS FOR THE PREPARATION OF A COMPOUND DERIVED FROM 2-TIAZOL-2-IL-QUINOLINA; INTERMEDIARY COMPOUNDS; AND PREPARATION PROCESS OF SUCH INTERMEDIATE COMPOUNDS.
EP1947076A4 (en) Process for producing aromatic compound and aromatic compound obtained by the process
BRPI0807194A2 (en) Compound, method for producing compost, collecting composition, and ore beneficiation method
EP2271213A4 (en) Methods for treating a condition characterized by dysfunction in protein homeostasis
EP2216312A4 (en) Process for producing organic compound and organic compound obtained by the same
BRPI0910454A2 (en) process for producing a polyclonal protein
EP1937892A4 (en) Method for treating lignocellulosic materials
ZA200708909B (en) Process for the double bond hydroisomerization of butenes
WO2007120638A3 (en) Methods and compositions for modulating glycosylation
DE602006004526D1 (en) Processing machine for wood elements
FR2881973B1 (en) COMPOSITE WIRE FOR ELECTROSION
WO2009124119A3 (en) Phosphodiesterase inhibitors and uses thereof
ZA200809916B (en) Presses for matters such as the grape harvest
PL2317867T3 (en) Method for treating hypersensitive teeth
IL201976A0 (en) Epoxy compound and method for manufacturing the same
EP1855547A4 (en) Methods for flavor enhancement
WO2010147375A3 (en) Method for screening for substance which inhibits interaction between beta amyloid peptide and vegf and inhibitor searched by same
EP2098523A4 (en) Novel compounds with affinity for amyloid
FI20050649A0 (en) Method for treating wood or wood products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10789702

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012515976

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13379213

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010789702

Country of ref document: EP